Laser Photonics & Echelon 1 Solutions Team Up To Deliver Laser Power to Defense Agencies

ORLANDO, Fla.--(BUSINESS WIRE)--Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for laser cleaning and other material processing applications, and Echelon 1 Solutions (E1S), a storage and logistics solutions provider for the military, have formed a partnership to bring laser cleaning and cutting technology to the defense industry. E1S is a Service-Disabled Veteran-Owned Small Business (SDVOSB) based in Tampa, Fla., which aims to fill a cr.

Jun 20, 2024 | www.businesswire.com

Q2 2024 EPS Estimates for Cresco Labs Inc. Raised by Echelon Wealth Partners (OTCMKTS:CRLBF)

Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Investment analysts at Echelon Wealth Partners upped their Q2 2024 earnings per share estimates for Cresco Labs in a note issued to investors on Wednesday, May 15th. Echelon Wealth Partners analyst A. Semple now anticipates that the company will post earnings per share of ($0.01) for the quarter, up from their prior forecast of ($0.02). Echelon Wealth Partners currently has a “Buy” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.05) per share. Echelon Wealth Partners also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.02) EPS and FY2025 earnings at ($0.02) EPS. CRLBF has been the subject of a number of other reports. Needham & Company LLC restated a “hold” rating on shares of Cresco Labs in a research note on Thursday. Roth Mkm lifted their target price on Cresco Labs from $1.75 to $2.00 and gave the stock a “neutral” rating in a research note on Thursday, March 14th. Finally, Wedbush lifted their target price on Cresco Labs from $2.50 to $3.00 and gave the stock an “outperform” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Cresco Labs has a consensus rating of “Moderate Buy” and an average target price of $2.63. Read Our Latest Stock Report on Cresco Labs Cresco Labs Stock Down 2.7 % Shares of Cresco Labs stock opened at $2.16 on Monday. The business’s 50 day simple moving average is $2.07 and its 200 day simple moving average is $1.84. Cresco Labs has a 52-week low of $1.00 and a 52-week high of $2.77. The firm has a market cap of $746.54 million, a PE ratio of -4.60 and a beta of 2.08. The company has a debt-to-equity ratio of 1.55, a quick ratio of 0.85 and a current ratio of 1.39. Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last announced its earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). Cresco Labs had a negative return on equity of 6.61% and a negative net margin of 20.32%. The business had revenue of $184.30 million for the quarter, compared to analyst estimates of $183.31 million. Cresco Labs Company Profile (Get Free Report) Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

May 20, 2024 | www.defenseworld.net

Q2 2024 Earnings Estimate for Cresco Labs Inc. (OTCMKTS:CRLBF) Issued By Wedbush

Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Equities research analysts at Wedbush lowered their Q2 2024 earnings per share estimates for Cresco Labs in a report released on Thursday, May 16th. Wedbush analyst G. Pascarelli now anticipates that the company will earn ($0.04) per share for the quarter, down from their prior estimate of ($0.03). Wedbush has a “Outperform” rating and a $3.00 price target on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.05) per share. Wedbush also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.11) EPS. Several other equities analysts have also weighed in on CRLBF. Needham & Company LLC reaffirmed a “hold” rating on shares of Cresco Labs in a research report on Thursday. Roth Mkm lifted their price target on shares of Cresco Labs from $1.75 to $2.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. Finally, Echelon Wealth Partners raised shares of Cresco Labs from a “hold” rating to a “buy” rating in a research report on Wednesday, March 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $2.63. Check Out Our Latest Stock Report on CRLBF Cresco Labs Price Performance Shares of CRLBF opened at $2.16 on Monday. The firm has a market cap of $746.54 million, a PE ratio of -4.60 and a beta of 2.08. The firm’s 50 day moving average price is $2.07 and its 200 day moving average price is $1.84. The company has a debt-to-equity ratio of 1.55, a quick ratio of 0.85 and a current ratio of 1.39. Cresco Labs has a twelve month low of $1.00 and a twelve month high of $2.77. Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $184.30 million for the quarter, compared to analyst estimates of $183.31 million. Cresco Labs had a negative net margin of 20.32% and a negative return on equity of 6.61%. About Cresco Labs (Get Free Report) Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

May 20, 2024 | www.defenseworld.net

Q2 2024 EPS Estimates for Cresco Labs Inc. (OTCMKTS:CRLBF) Boosted by Alliance Global Partners

Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Analysts at Alliance Global Partners increased their Q2 2024 earnings per share (EPS) estimates for Cresco Labs in a research note issued on Wednesday, May 15th. Alliance Global Partners analyst A. Grey now forecasts that the company will earn ($0.01) per share for the quarter, up from their previous forecast of ($0.04). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.05) per share. Alliance Global Partners also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.03) EPS and FY2025 earnings at ($0.02) EPS. Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The business had revenue of $184.30 million for the quarter, compared to the consensus estimate of $183.31 million. Cresco Labs had a negative return on equity of 6.61% and a negative net margin of 20.32%. Several other equities research analysts also recently issued reports on CRLBF. Roth Mkm increased their target price on Cresco Labs from $1.75 to $2.00 and gave the stock a “neutral” rating in a research report on Thursday, March 14th. Wedbush increased their price objective on Cresco Labs from $2.50 to $3.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Cresco Labs in a research note on Thursday. Finally, Echelon Wealth Partners raised Cresco Labs from a “hold” rating to a “buy” rating in a research note on Wednesday, March 13th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $2.63. Read Our Latest Analysis on CRLBF Cresco Labs Trading Down 2.7 % OTCMKTS:CRLBF opened at $2.16 on Monday. The company has a market cap of $746.54 million, a P/E ratio of -4.60 and a beta of 2.08. The stock’s fifty day moving average price is $2.07 and its two-hundred day moving average price is $1.84. Cresco Labs has a 1 year low of $1.00 and a 1 year high of $2.77. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.39 and a quick ratio of 0.85. Cresco Labs Company Profile (Get Free Report) Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. Read More Five stocks we like better than Cresco Labs 3 Healthcare Dividend Stocks to Buy MarketBeat Week in Review – 5/13 – 5/17 How to Find Undervalued Stocks Take-Two Interactive Software Offers 2nd Chance for Investors What is a Low P/E Ratio and What Does it Tell Investors? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

May 20, 2024 | www.defenseworld.net

AM Best : Removes From Under Review With Negative Implications and Affirms Credit Ratings of Guardian Insurance Company, Inc. and Echelon Property & Casualty Insurance Company

Aug 07, 2020 | www.marketscreener.com

Echelon Corporation to Announce Fourth Quarter 2015 Results on February 11th

SANTA CLARA, Calif.--(BUSINESS WIRE)--Echelon Corporation (NASDAQ: ELON), a leading independent control networking company for the Industrial Internet of Things (IIoT), will announce results for the fourth quarter ended December 31, 2015, on Thursday, February 11, 2016, after market close. The Company will hold a conference call for investors and analysts the same day, February 11, 2016, at 4:30 p.m. Eastern Time. Interested parties can listen to the call via live webcast on the Investor Relations section of the Echelon website at http://www.echelon.com. To access the live call, dial (800) 708-4539 in North America or (847) 619-6396 outside of North America, and provide the participant pass code 41509590. An archived replay of the webcast will be available on the Investor Relations section of the Echelon website approximately two hours following the end of the call. About Echelon Corporation Echelon Corporation (NASDAQ: ELON), a pioneer in developing open-standard control networking platforms, delivers elements necessary to design, install, monitor and control industrial-strength ‘communities of devices’ within the lighting, building automation, Internet of Things and related markets worldwide. Echelon sells its lighting products under the Lumewave by Echelon brand and its building automation and other IIoT-related products as part of its IzoT™ platform. With more than 100 million Echelon-powered devices installed worldwide, Echelon helps its customers easily and safely migrate existing control systems to the most modern platforms, while bringing new devices and applications into an ever-growing global Industrial Internet. Echelon helps its customers reduce operational costs, enhance satisfaction and safety, grow revenues and perform better in both established and emerging markets. More information about Echelon can be found at http://iiot.echelon.com, or www.echelon.com and at the company's blog at blog.echelon.com. This press release may contain statements relating to future plans, events or performance. Such statements may involve risks and uncertainties, the risk that Echelon's offerings by themselves or combined with other applications or offerings do not perform as designed or do not offer the expected benefits and savings; risks associated with international sales; and other risks identified in Echelon's SEC filings. Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Echelon undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Feb 01, 2016 | www.businesswire.com